Expressive arts intervention for adults with vision loss due to aging
Official title: Unlocking Limitations Through Arts: A Mixed Methods Study on the Effectiveness of an Expressive Arts-based Intervention on Psychosocial Wellbeing of Adults With Age-related Visual Impairment
Run by The University of Hong Kong · NCT05675150 · Data updated 2026-11-12
This study is testing a creative arts program to see if it can help adults aged 50 to 80 with vision loss from aging feel better and adjust to their changes in sight.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 80 Years |
| Sex | All |
| Enrollment | 154 (estimated) |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Status | Recruiting |
| Started | May 1, 2023 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | May 15, 2025 |
| Trial ID | NCT05675150 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are Chinese-speaking adults aged 50 to 80 diagnosed with age-related macular degeneration.
✕Probably not a fit
Patients who are totally blind or have significant comorbidities that impair their ability to participate may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness of a multimodal, expressive arts-based intervention designed for adults aged 50 to 80 with age-related macular degeneration (AMD). The intervention aims to enhance psychosocial wellness and help participants adjust to gradual vision loss through creative engagement. Participants will be randomly assigned to either the expressive arts intervention group or a treatment-as-usual control group over an 8-week period. The study will assess various outcomes, including psychosocial adaptation, quality of life, and symptoms of depression and anxiety.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the psychosocial well-being and quality of life for patients with age-related macular degeneration.
How similar studies have gone: While expressive arts interventions have shown promise in other populations, this specific approach for AMD is relatively novel and untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants are community-dwelling, Chinese-speaking adults aged between 50 and 80, with the diagnosis of age-related macular degeneration in one or both eyes of all different etiologies Exclusion Criteria: * Inability to understand the Chinese language, as well as a diagnosis of total blindness, presence of other significant physical, psychological, and cognitive comorbidities that would hinder the participant from completing the study will be excluded.
Where it's running
-
Centre on Behavioral Health, The University of Hong Kong
Hong Kong, Hong Kong Recruiting
Study contacts
- Principal investigator: Rainbow Ho — Director/Professor
- Study coordinator: Rainbow Ho
- Email: tinho@hku.hk
- Phone: (852)28315158
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding Age-Related Macular Degeneration and Its Progression
This study looks at how age-related macular degeneration develops and progresses by comparing people with the condition to healthy individuals, using non-invasive tests and personal feedback.
-
Blepharoptosis After Repeated Anti-VEGF Injections in One Eye
This study tests whether repeated intravitreal anti-VEGF injections in one eye affect eyelid position compared with the untreated fellow eye.
-
First-in-human test of ARO-033 in adults
This study tests whether ARO-033 is safe and tolerable, and how it behaves in the body, in healthy adults and in adults with age-related macular degeneration.
-
Predicting Risk of AMD Progression Using Imaging in Aging Eyes
Researchers are test a new screening approach to detect early AMD and monitor its progression in adults 55 and older, to see if personalized monitoring can help in community settings.
-
C.001 for retinal degeneration: a first-in-human dose-escalation safety test
A first-in-human study will test the safety and tolerability of a single subretinal injection of C.001 in adults with retinal diseases involving retinal pigment epithelium degeneration.
-
Central microperimetry and radial OCT in geographic atrophy
We will test whether central microperimetry and radial OCT scans can more accurately measure how geographic atrophy progresses toward the fovea in people with or at risk for GA from age-related macular degeneration.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.